What is Bicara Therapeutics's return on equity?

Bicara Therapeutics (BCAX) reported return on equity of -32.3% in Q1 2026.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Bicara Therapeutics BCAX Return on equity

Return on equity at other companies

Eli LillyLLY

107.6%+29.9pp

AmgenAMGN

101.3%-4.4pp

ArriVent BioPharma, Inc.AVBP

-55.2%+8.0pp

ImmunomeIMNM

-50.1%-10.8pp

Arcus BiosciencesRCUS

-70%+8.4pp

Syndax PharmaceuticalsSNDX

-189.5%-8,509pp

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.64B+81.4%

Enterprise value$1.32B+288%

Returns & leverage

See full

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Calculated from Bicara Therapeutics’s reported figures.

net income/total stockholders equity=-32.3%

Based on trailing twelve months.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's return on equity?: Bicara Therapeutics (BCAX) reported return on equity of -32.3% in Q1 2026.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.